Thus, a pressing question remains unanswered in the clinic: should agents targeting signalling molecules of the AKT/mTOR axis, like alpelisib and capivasertib, be solely administered to patients whose tumours harbour genomic alterations of genes encoding for members of this pathway? Here, MTOR is linked to neoplasm.